Endologix Announces 2005 Fourth Quarter and Year End Financial Results Conference Call
February 15 2006 - 4:37PM
Business Wire
Endologix, Inc. (Nasdaq:ELGX), the developer of the Powerlink(R)
System for the minimally invasive treatment of abdominal aortic
aneurysms (AAA), today announced that the Company will hold a
conference call to discuss 2005 fourth quarter and year end
financial results on Thursday, February 23, 2006, at 5:00 p.m.
Eastern Time (2:00 p.m. Pacific Time). Individuals interested in
listening to the live conference call may do so by dialing (888)
463-4487 toll free within the U.S. and Canada, or (706) 634-5615
for international callers. A telephone replay of the conference
call will be available for 48 hours beginning February 23 within
two hours after the conclusion of the call, by dialing (800)
642-1687 domestically or (706) 645-9291 internationally, and
entering reservation number 4699202. The conference call can be
heard live via audio webcast at the Company's Web site:
www.endologix.com. Please go to the Interviews/Presentations page
on the Investor Relations section of the Web site. A replay will
also be available for 14 days. About Endologix Endologix, Inc.
develops and manufactures minimally invasive treatments for
vascular diseases. Endologix's Powerlink System is an endoluminal
stent graft (ELG) for treating abdominal aortic aneurysms (AAA).
AAA is a weakening of the wall of the aorta, the largest artery in
the body, resulting in a balloon-like enlargement. Once AAA
develops, it continues to enlarge and, if left untreated, becomes
increasingly susceptible to rupture. The overall patient mortality
rate for ruptured AAA is approximately 75%, making it the
thirteenth leading cause of death in the U.S. In October 2004,
Endologix received approval to market the Powerlink in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024